HALIFAX, July 24 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF) a developer and marketer of rapid diagnostics, announced today
that further to the news release issued June 5, 2009, it has received approval
from the TSX Venture Exchange to settle $479,431 of debt through the issuance
of common shares. The Company will issue 6,849,011 common shares at a price of
$0.07 per share based on the June 4, 2009 close. Shares issued under this
agreement will be subject to a four month hold period.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.%SEDAR: 00013053E
For further information: Andrea Young, Corporate Communications, (902)
450-1588, ayoung@medmira.com
